Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that the Company has appointed Scott Myers as President
and Chief Executive Officer, and a member of the Board of
Directors, effective today February 6, 2023. Mr. Myers has more
than 30 years of biopharmaceutical and medical technology
experience, and has held global executive leadership and director
roles at numerous commercial- and development-stage
biopharmaceutical companies. He succeeds Jonathan Violin, Ph.D. who
has led Viridian since its inception in 2020.
“Our progress and growth since founding Viridian have been
nothing but extraordinary. With our first Phase 3 trial in TED
underway, and a potential best-in-class subcutaneous strategy
advancing rapidly behind it, the time is right to advance the
company through its next stage of growth,” said Jonathan Violin,
Ph.D., Viridian’s co-founder and founding CEO. “Scott brings to
Viridian extensive late-stage clinical development, global
commercial, and executive leadership experience with a proven track
record of creating value. His appointment puts Viridian in a
position to build upon the Company’s strong foundation to achieve
our shared vision of becoming a fully-integrated biopharmaceutical
company. I am proud of what we have built at Viridian, and excited
about the future of the Company under Scott’s leadership.”
Mr. Myers most recently served as the CEO and Director of AMAG
Pharmaceuticals, where he led its turnaround and strategic sale to
Covis Pharma. Prior to AMAG, he served as CEO and Chairman of the
Board of Rainier Therapeutics, a late-stage oncology company.
Previous roles include serving as CEO, President and Director of
Cascadian Therapeutics until its acquisition by Seagen, and as CEO
of Aerocrine AB, a medical technology company. While CEO of these
companies, Mr. Myers and his teams transformed the companies to
focus on creating and advancing innovative products to deliver
significant shareholder value.
“I am honored to lead Viridian at this exciting time of
continued growth. I look forward to building on the remarkable
accomplishments that Jonathan and the leadership team have
achieved, and to executing on our vision of evolving Viridian into
a fully-integrated biopharmaceutical company,” said Mr. Myers.
“Viridian has a unique opportunity to bring differentiated
medicines to market for patients suffering from TED, and to broaden
and advance a pipeline of promising next-generation medicines for
other serious and rare diseases. The team and I will be focused on
clinical execution for our lead programs in TED, and on building
our initial commercial team for Viridian’s future phases of
growth.”
Mr. Myers is currently on the board of directors at Dynavax
Technologies, Harpoon Therapeutics, Ironshore Therapeutics, Selecta
Biosciences, and Sensorion. He was previously an Independent
Director at Trillium Therapeutics until its acquisition by
Pfizer.
Mr. Myers began his career in management consulting and then
moved into the pharmaceutical industry through senior commercial
leadership roles in the United States and globally at Johnson &
Johnson, DOV Pharmaceuticals, and UCB. He holds a Bachelor of Arts
degree in Biology from Northwestern University and a Master of
Business Administration from the University of Chicago Booth School
of Business.
Notice of Issuance of Inducement Grant
Viridian also announced the grant of an inducement award to Mr.
Myers as an inducement material to Mr. Myers’ employment pursuant
to Rule 5635(c)(4) of the Nasdaq Listing Rules. In connection with
his commencement of employment, Mr. Myers was granted an inducement
award consisting of an option to purchase 1,000,000 shares of
Viridian’s common stock and 250,000 restricted stock units of
Viridian’s common stock. The shares underlying the option and the
restricted stock units vest and, in the case of the option, become
exercisable as follows: one quarter of the underlying shares on the
first anniversary of February 6, 2023 and then in equal monthly
installments thereafter over the following 36 months, subject to
Mr. Myers’ continued service to the Company. The exercise price of
the stock option will equal the closing price of the Company's
common stock on February 6, 2023, the date of the grant.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on
engineering and developing potential best-in-class medicines for
patients with serious and rare diseases. Viridian’s expertise in
antibody discovery and engineering enables it to develop
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
recently initiated its first global Phase 3 trial called ‘THRIVE’
to evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also evaluating VRDN-001 in a Phase 2
proof-of-concept trial in patients with chronic TED. In addition to
its intravenously administered VRDN-001 program, the Company is
advancing two candidates for its subcutaneous strategy with the
goal of providing a more conveniently administered therapy to
patients with TED. Viridian is developing multiple preclinical
assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit https://www.viridiantherapeutics.com.
Follow Viridian on LinkedIn.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will," or
"would" or other similar terms or expressions that concern the
Company’s expectations, plans and intentions. Forward-looking
statements include, without limitation, statements regarding the
statements regarding the Company’s clinical development plans and
potential and commercialization strategies. New risks and
uncertainties may emerge from time to time, and it is not possible
to predict all risks and uncertainties. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements. Such forward-looking
statements are subject to a number of material risks and
uncertainties including, but not limited to, those risks set forth
under the caption “Risk Factors” in the Company’s Annual Report on
Form 10-K filed with the Securities and Exchange
Commission (SEC) on March 11, 2022 and other
subsequent disclosure documents filed with the SEC. Any
forward-looking statement speaks only as of the date on which it
was made. Neither the Company, nor its affiliates, advisors, or
representatives, undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by law.
These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
Investor and Media ContactViridian
Therapeutics, Inc.
Todd James, 617-272-4691Senior Vice President, Corporate Affairs
and Investor RelationsIR@viridiantherapeutics.com
Louisa Stone, 508-808-2400Manager, Investor
RelationsIR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024